| Literature DB >> 23738331 |
Claudia Ramos de Rainho1, Sérgio Machado Corrêa, José Luiz Mazzei, Claudia Alessandra Fortes Aiub, Israel Felzenszwalb.
Abstract
Air pollution toxic effects are mainly attributed to small inhalable particulates with an aerodynamic diameter of less than 2.5 µ m (PM 2.5). Our objective was to investigate mutagenic and clastogenic activity in PM samples collected in Rio de Janeiro. Samples were collected using a high-volume sampler at three sites: with low traffic and (2) and (3) with a heavy traffic. Six polycyclic aromatic hydrocarbons (PAHs) were quantified by gas chromatography/mass spectrometry (GC/MS). Salmonella typhimurium TA98 and the derivative strains YG1021 and YG1024 were used in mutagenicity assays in the presence of organic extracts (10-50 µ g/ plate) with and without exogenous metabolization. Allium cepa test was performed to evaluate possible cytotoxic and clastogenic activities. The highest PM 2.5 µ m (132.73 µ m/m(3)) and PAH values (1.22 ng/m(3) for benzo(a)pyrene) were detected at site 3. High mutagenic frameshift responses in absence and presence of metabolic activation were detected at site 3. The participation of nitroarenes and dinitroarenes was detected in the total mutagenicity of the extracts studied. The cytotoxic effect and the abnormalities detected by Allium cepa test can be attributed to the PAH nitroderivatives in the organic extracts. Evaluation of the genotoxicity of urban airborne particulate matter is important as a basis for decision making by regulatory authorities.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23738331 PMCID: PMC3659438 DOI: 10.1155/2013/765352
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Collection sites, air volume, PM 2.5 µm concentration, and extractable organic matter (EOM) of the samples analyzed.
| Site | Month | Air volume | PM 2.5 | PM 2.5 | EOM |
|---|---|---|---|---|---|
| August | 1513 ± 36 | 17.51/18.63/13.63/45.09 | 23.71 ± 14.41 | 9.66 | |
| 1 | September | 1582 ± 53 | 23.43/43.83/40.24/14.48 | 30.49 ± 13.89 | 7.92 |
| October | 1623 ± 148 | 14.46/13.61/21.73/11.27 | 15.27 ± 4.51 | 5.54 | |
|
| |||||
| August | 1541 ± 1 | 40.19/44.59/44.01/51.77 | 45.14 ± 4.83 | 7.76 | |
| 2 | September | 1554 ± 31 | 13.76/34.66/41.58/15.20 | 26.30 ± 13.94 | 7.24 |
| October | 1640 ± 194 | 22.48/36.47/11.74/25.08 | 23.94 ± 10.15 | 5.48 | |
|
| |||||
| August | 430 ± 67 | 42.38/168.85/35.60/131.33 | 94.54 ± 66.00 | 20.93 | |
| 3 | September | 420 ± 40 | 68.85/167.33/91.55/61.01 | 97.18 ± 48.52 | 21.44 |
| October | 359 ± 6 | 77.15/239.77/75.68/138.33 | 132.73 ± 77.09 | 25.05 | |
1: UERJ; 2: Avenida Brasil; 3: Rebouças tunnel; S.D.: standard deviation; airborne PM 2.5 µm samples were collected for 24 h at sites 1 and 2 and 6 h at site 3. Six-h time filter saturation at site 3.
Figure 1(a)–(c) PAH concentrations in ng/m3 of the three sites. Benzo(a)pyrene not detected at sites 1 and 2.
Induced mutagenic by airborne particulate matter organic extracts (rev/m3).
| Site | Month | TA98 | YG1021 | YG1024 | |||
|---|---|---|---|---|---|---|---|
| −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | ||
| August | n.d.a | 15.80 ± 1.40 | 13.90 ± 0.80 | 9.50 ± 1.40 | 38.20 ± 1.60 | 15.50 ± 1.40 | |
| 1 | September | n.d.a | 13.00 ± 2.10 | 6.10 ± 1.30 | n.d.a | 15.80 ± 2.50 | 3.40 ± 0.80 |
| October | n.d.a | n.d.a | 10.20 ± 1.30 | 6.40 ± 1.10 | 2.90 ± 0.60 | n.d.a | |
|
| |||||||
| August | 17.00 ± 1.90 | 1.50 ± 0.50 | 17.30 ± 1.80 | 5.70 ± 1.60 | 43.40 ± 8.50 | 10.70 ± 1.80 | |
| 2 | September | 5.70 ± 0.90 | n.d.a | 13.90 ± 1.30 | 6.40 ± 1.24 | 11.70 ± 2.50 | 6.00 ± 0.70 |
| October | n.d.a | n.d.a | 4.90 ± 0.70 | n.d.a | 3.80 ± 0.30 | n.d.a | |
|
| |||||||
| August | 39.60 ± 11.90 | 13.00 ± 2.30 | 4.40 ± 1.90 | 3.10 ± 0.80 | 28.30 ± 3.10 | 2.30 ± 0.80 | |
| 3 | September | 56.40 ± 20.60 | 58.70 ± 11.80 | 63.00 ± 3.20 | 26.60 ± 3.90 | 57.00 ± 6.90 | 49.30 ± 3.90 |
| October | 9.30 ± 1.80 | 46.50 ± 4.20 | 35.40 ± 0.80 | 18.30 ± 1.80 | 22.80 ± 2.00 | 6.00 ± 2.00 | |
1: UERJ; 2: Avenida Brasil; 3: Rebouças tunnel. n.d.a: not detected. Negative control: DMSO for the mutagenicity assay without S9 mix was TA98, (28 ± 5); YG1021, (20 ± 2); YG1024, (18 ± 4). DMSO for the mutagenicity assay with S9 mix was TA98, (43 ± 3); YG1021, (35 ± 23); YG1024, (18 ± 5). Positive controls for the mutagenicity assay without S9 mix were 4-nitroquinoline oxide (0.5 µg/plate) for TA98, (853 ± 72); YG1021, (719 ± 75); YG1024, (1021 ± 54). Positive controls for the mutagenicity assay with S9 mix were 2-aminofluorene (1 µg/plate) for TA98, (214 ± 42); YG1021, (150 ± 32); YG1024, (219 ± 81).
Mitotic index and percentage of mitosis stages and mitotic aberrations in the root tip cells of A. cepa treated with organic extract derived at site 1.
| Month |
| Mitotic index | % P. | % M. | % A. | % T. | % T.A. | % MCN | % Bridge | % Break | % Lagging |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | 0.03 ± 0.00 | 1.40 | 0.90 | 0.50 | 1.10 | 0.07 | 0.05 | 0.00 | 0.00 | 0.02 | |
| 5 | 0.04 ± 0.01 | 3.20* | 0.80 | 0.60 | 0.30 | 0.12 | 0.02 | 0.02 | 0.00 | 0.08 | |
| August | 10 | 0.02 ± 0.00* | 0.20* | 1.00 | 0.40 | 1.00 | 0.35 | 0.20 | 0.10 | 0.00 | 0.05 |
| 15 | 0.01 ± 0.01* | 0.03* | 0.30 | 0.10 | 0.20* | 0.55 | 0.55 | 0.00 | 0.00 | 0.00 | |
| 20 | 0.01 ± 0.01* | 0.02* | 0.10* | 0.03* | 0.20* | 0.05 | 0.03 | 0.00 | 0.02 | 0.00 | |
| 25 | 0.00 ± 0.00* | 0.00* | 0.00* | 0.00* | 0.00* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NC | 0.02 ± 0.01 | 0.80 | 0.60 | 0.20 | 0.50 | 0.15 | 0.00 | 0.05 | 0.05 | 0.05 | |
| 5 | 0.04 ± 0.02 | 1.10 | 1.30 | 0.80 | 0.50 | 0.54 | 0.04 | 0.20 | 0.08 | 0.22 | |
| September | 10 | 0.07 ± 0.03 | 2.00 | 2.50* | 1.50* | 1.50 | 1.30* | 0.10 | 0.40 | 0.40 | 0.40 |
| 15 | 0.01 ± 0.01 | 0.50 | 0.30 | 0.30 | 1.30 | 0.60 | 0.40 | 0.05 | 0.05 | 0.10 | |
| 20 | 0.06 ± 0.05 | 2.00 | 2.00 | 1.00 | 1.40 | 1.08* | 0.06 | 0.33 | 0.26 | 0.43 | |
| 25 | 0.01 ± 0.01 | 0.50 | 0.50 | 0.10 | 0.30 | 0.28 | 0.03 | 0.06 | 0.16 | 0.03 | |
| NC | 0.02 ± 0.00 | 1.40 | 0.40 | 0.00 | 0.00 | 0.10 | 0.08 | 0.00 | 0.02 | 0.00 | |
| 5 | 0.11 ± 0.05 | 7.00 | 0.70 | 0.40 | 2.60 | 0.10 | 0.00 | 0.00 | 0.07 | 0.03 | |
| October | 10 | 0.05 ± 0.05 | 2.70 | 0.70 | 0.50 | 1.60 | 0.18 | 0.00 | 0.03 | 0.10 | 0.05 |
| 15 | 0.06 ± 0.04 | 2.60 | 1.30 | 0.30 | 2.30 | 0.29* | 0.07 | 0.05 | 0.12* | 0.05 | |
| 20 | 0.05 ± 0.03 | 2.50 | 1.10 | 0.40 | 0.80 | 0.10 | 0.00 | 0.02 | 0.03 | 0.05 | |
| 25 | 0.06 ± 0.03 | 3.20 | 1.00 | 0.50 | 1.00 | 0.31 | 0.03 | 0.00 | 0.18 | 0.10 |
P.: prophase; M.: metaphase; A.: anaphase; T.: telophase; T.A.: total abnormalities; MCN.: micronucleus; NC.: negative control—DMSO; positive control = benzo(a)pyrene 10 µg/mL (mitotic index = 0.00*; % T.A. = 0.20; % MCN = 0.16; % bridge = 0.04) *P ≤ 0.05.
Mitotic index and percentage of mitosis stages and mitotic aberrations in the root tip cells of A. cepa treated with organic extract derived at site 2.
| Month |
| Mitotic index | % P. | % M. | % A. | % T. | % T.A. | % MCN | % Bridge | % Break | % Lagging |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | 0.08 ± 0.03 | 4.50 | 1.90 | 0.40 | 1.10 | 0.30 | 0.18 | 0.07 | 0.00 | 0.05 | |
| 5 | 0.07 ± 0.03 | 3.20 | 1.60 | 0.90* | 1.80 | 0.57 | 0.25 | 0.17 | 0.00 | 0.15 | |
| August | 10 | 0.04 ± 0.01* | 1.80* | 0.80 | 0.40 | 0.60 | 0.41 | 0.03 | 0.06 | 0.16 | 0.16 |
| 15 | 0.04 ± 0.01* | 0.33* | 3.26 | 0.56 | 0.36 | 0.75* | 0.03 | 0.23* | 0.26* | 0.23 | |
| 20 | 0.04 ± 0.02* | 2.53 | 1.23 | 0.46 | 0.76 | 0.19 | 0.00 | 0.00 | 0.16 | 0.03 | |
| 25 | 0.04 ± 0.01* | 0.10* | 1.40 | 0.90* | 1.40 | 0.70 | 0.00 | 0.50* | 0.10 | 0.10 | |
| NC | 0.02 ± 0.01 | 0.80 | 0.60 | 0.20 | 0.50 | 0.15 | 0.00 | 0.05 | 0.05 | 0.05 | |
| 5 | 0.04 ± 0.02 | 1.10 | 1.30 | 0.80 | 0.50 | 0.54 | 0.04 | 0.20 | 0.08 | 0.22 | |
| September | 10 | 0.07 ± 0.03 | 2.00 | 2.50* | 1.50* | 1.50 | 1.30* | 0.10 | 0.40 | 0.40 | 0.40 |
| 15 | 0.01 ± 0.01 | 0.50 | 0.30 | 0.30 | 0.01* | 0.60 | 0.40 | 0.05 | 0.05 | 0.10 | |
| 20 | 0.06 ± 0.05 | 2.00 | 2.00 | 1.00 | 1.40 | 1.08* | 0.06 | 0.33 | 0.26 | 0.43 | |
| 25 | 0.01 ± 0.01 | 0.50 | 0.50 | 0.10 | 0.30 | 0.28 | 0.03 | 0.06 | 0.16 | 0.03 | |
| NC | 0.05 ± 0.02 | 3.90 | 0.50 | 0.20 | 0.30 | 0.30 | 0.10 | 0.00 | 0.10 | 0.10 | |
| 5 | 0.05 ± 0.01 | 2.00 | 1.50 | 0.70 | 1.30 | 0.67 | 0.00 | 0.17* | 0.30 | 0.20 | |
| October | 10 | 0.07 ± 0.01 | 1.70 | 1.80 | 0.80 | 3.20* | 1.05 | 0.00 | 0.10 | 0.75 | 0.20 |
| 15 | 0.00 ± 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 20 | 0.00 ± 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.03 | 0.00 | 0.00 | |
| 25 | 0.00 ± 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P.: prophase; M.: metaphase; A.: anaphase; T.: telophase; T.A.: total abnormalities; MCN.: micronucleus; NC.: negative control—DMSO; positive control = benzo(a)pyrene 10 µg/mL (mitotic index = 0.00*; % T.A. = 0.20; % bridge = 0.10; % break =0.10) *P ≤ 0.05.
Mitotic index and percentage of mitosis stages and mitotic aberrations in the root tip cells of A. cepa treated with organic extract derived at site 3.
| Month |
| Mitotic index | % P. | % M. | % A. | % T. | % T. A. | % MCN | % Bridge | % Break | % Lagging |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | 0.04 ± 0.02 | 2.60 | 0.70 | 0.40 | 1.00 | 0.12 | 0.07 | 0.00 | 0.00 | 0.05 | |
| 5 | 0.03 ± 0.02 | 0.70 | 0.40 | 0.90 | 0.30 | 0.30 | 0.04 | 0.02 | 0.00 | 0.14 | |
| August | 10 | 0.07 ± 0.03 | 2.70 | 2.20 | 0.90 | 2.10 | 0.50* | 0.30 | 0.10 | 0.00 | 0.10 |
| 15 | 0.06 ± 0.04 | 1.70 | 2.20 | 1.10* | 1.00 | 0.26 | 0.10 | 0.13 | 0.00 | 0.03 | |
| 20 | 0.04 ± 0.02 | 1.60 | 1.40 | 0.70 | 1.00 | 0.16 | 0.10 | 0.03 | 0.00 | 0.03 | |
| 25 | 0.03 ± 0.01 | 1.30 | 0.90 | 0.60 | 0.60 | 0.15 | 0.00 | 0.00 | 0.00 | 0.15 | |
| NC | 0.08 ± 0.06 | 6.00 | 1.60 | 0.90 | 1.40 | 0.67 | 0.10 | 0.08 | 0.20 | 0.42 | |
| 5 | 0.04 ± 0.03 | 3.10 | 1.00 | 0.40 | 2.10 | 2.05* | 1.63* | 0.12 | 0.22 | 0.05 | |
| September | 10 | 0.03 ± 0.03 | 1.00* | 0.80 | 0.40 | 0.60 | 0.78 | 0.25 | 0.03 | 0.20 | 0.30 |
| 15 | 0.10 ± 0.10 | 3.30 | 3.20 | 1.20 | 2.00 | 1.80 | 0.00 | 1.00* | 0.60 | 0.20 | |
| 20 | 0.00 ± 0.00* | 0.00* | 0.00* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 25 | 0.02 ± 0.01* | 1.00* | 0.10* | 0.00 | 0.70 | 0.12 | 0.00 | 0.00 | 0.10 | 0.02 | |
| NC | 0.08 ± 0.01 | 5.70 | 0.70 | 0.60 | 1.20 | 0.30 | 0.00 | 0.05 | 0.05 | 0.20 | |
| 5 | 0.09 ± 0.01 | 3.80 | 1.60 | 0.80 | 2.90 | 0.60 | 0.00 | 0.00 | 0.50* | 0.10 | |
| October | 10 | 0.06 ± 0.05 | 1.90* | 0.70 | 0.40 | 2.70 | 0.28 | 0.10 | 0.03 | 0.05 | 0.10 |
| 15 | 0.03 ± 0.01* | 0.90* | 0.70 | 0.50 | 0.80 | 0.40 | 0.20 | 0.10 | 0.00 | 0.10 | |
| 20 | 0.00 ± 0.00* | 0.00* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 25 | 0.01 ± 0.02* | 0.80* | 0.00 | 0.03 | 0.03 | 0.33 | 0.00 | 0.03 | 0.00 | 0.00 |
P.: prophase; M.: metaphase; A.: anaphase; T.: telophase; T.A.: total abnormalities; MCN.: micronucleus; NC.: negative control—DMSO; positive control = benzo(a)pyrene 10 µg/mL (mitotic index = 0.00*; % T.A. = 0.00; %) *P ≤ 0.05.